Hematology/oncology transplant units managing alloSCT patients
Key Highlights
Endothelial cells (ECs) are central in regulating vascular tone, coagulation, inflammation, and immune responses during alloSCT.
Major endothelial injury syndromes post-alloSCT include sinusoidal obstruction syndrome/venoocclusive disease (SOS/VOD), transplant-associated thrombotic microangiopathy (TA-TMA), and refractory acute graft-versus-host disease (aGVHD).
Functional heterogeneity of ECs complicates diagnosis and biomarker interpretation for endothelial complications after alloSCT.
Guideline-Based Recommendations
Diagnosis
Use clinical criteria combined with endothelial biomarkers to diagnose SOS/VOD, TA-TMA, and refractory aGVHD.
Consider biomarkers such as von Willebrand factor (vWF), thrombomodulin (TM), ICAM-1, VCAM-1, angiopoietin-2 (ANG2), and ST2 for endothelial injury assessment.
Recognize the limitations of current diagnostic criteria due to endothelial functional heterogeneity and overlapping clinical features.
Management
Targeted treatment interventions such as terminal complement blockade may benefit high-risk TA-TMA patients.
Monitor and manage endothelial injury syndromes promptly to reduce mortality and morbidity post-alloSCT.
Monitoring & Follow-up
Regular assessment of endothelial biomarkers to predict and monitor endothelial injury syndromes.
Close clinical monitoring for signs of SOS/VOD (weight gain, ascites, hepatomegaly, jaundice), TA-TMA (microangiopathic hemolytic anemia, thrombocytopenia), and aGVHD.
Risks
High mortality rates associated with severe TA-TMA (up to 90%).
Endothelial dysfunction contributes to multiple post-transplant complications including refractory aGVHD and vascular injury syndromes.
Pre-existing endothelial vulnerability and comorbidities increase risk of endothelial injury post-alloSCT.
Patient & Prescribing Data
Allogeneic stem cell transplant recipients with variable endothelial vulnerability
Individualized approaches considering endothelial biomarker profiles and risk stratification may optimize outcomes; targeted therapies like complement blockade show promise in TA-TMA.
Clinical Best Practices
Assess patient-specific endothelial vulnerability prior to alloSCT to anticipate risk of endothelial complications.
Incorporate endothelial biomarkers into diagnostic and prognostic algorithms for early detection of SOS/VOD, TA-TMA, and refractory aGVHD.
Recognize and address the functional heterogeneity of endothelial cells when interpreting clinical and laboratory findings.
Implement multidisciplinary management strategies including hematology, hepatology, and immunology expertise for complex endothelial injury syndromes.
